Dyne received FDA Breakthrough Therapy Designation and submitted revised protocols based on feedback regarding its therapies for DMD and myotonic dystrophy type 1.

The entities involved

• Dyn →

  Internet performance company

  • Trump-era tariffs are reportedly benefiting certain AI stocks, coinciding with the spin-off of Millrose Properties, Inc. from Lennar Corporation.Sun 14:13
• FDA →
  • Generic medicine services are seeking approval for launch from the FDA.Mon 17:49
  • A company is seeking FDA feedback on its NEO212 program, with a meeting scheduled at the FDA's White Oak campus.Mon 14:56

Related events

• The US administration rejected a proposed FDA-style central AI regulator while acknowledging the need to compete with China in the AI race.Jul 5
• FDA review extended for ruxolitinib cream, while Incyte benefits from potential Trump-era tariffs, leading to analyst upgrades and recommendations.Jun 8
• FDA is willing to review updated submissions, while biotech hubs leverage AI to ease clinical development bottlenecks.Aug 28
• FDA grants emergency authorization for cell therapy amid policy shifts reducing federal science funding.Sep 10
• Ro Khanna compared his AI regulatory proposal to the FDA model.Thu 12:49